Castleman Disease clinical trials
The registry lists 22 studies for Castleman Disease across more than 10 countries. 9 are recruiting or about to start. 14 of them are mainly about Castleman Disease (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-05. Counting its narrower condition Multi-centric Castleman's Disease too: 41 studies, 14 open.
Get an email when these change. Save the Castleman Disease studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
University of Pennsylvania (4) · National Cancer Institute (NCI) (2) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (1) · M.D. Anderson Cancer Center (1) · Case Comprehensive Cancer Center (1) · UNC Lineberger Comprehensive Cancer Center (1) · University of Siena (1) · Castleman Disease Collaborative Network (1)
What is being tested here
Drugs under test in Castleman Disease studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Nintedanib | 1 | 0 | 1 |
| Ruxolitinib | 1 | 0 | 1 |
| Tocilizumab | 0 | 0 | 2 |
| Sirolimus | 0 | 0 | 1 |
| Siltuximab | 0 | 0 | 1 |
| Bevacizumab | 0 | 0 | 1 |
| Temsirolimus | 0 | 0 | 1 |
| Nelfinavir | 0 | 0 | 1 |
| Rituximab | 0 | 0 | 1 |
| Silmitasertib | 0 | 0 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The study
- Sep 2027International Registry for Patients With Castleman Disease · University of Pennsylvania
Who these studies take
Of the 8 Castleman Disease studies recruiting now, 7 (88%) set no upper age limit and 0 (0%) stop at 75 or younger. 3 (38%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (13%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 3 (38%) | 3 (38%) |
| 18 | 8 (100%) | 8 (100%) |
| 30 | 8 (100%) | 8 (100%) |
| 40 | 8 (100%) | 8 (100%) |
| 50 | 8 (100%) | 8 (100%) |
| 65 | 8 (100%) | 8 (100%) |
| 75 | 8 (100%) | 8 (100%) |
| 85 | 7 (88%) | 7 (88%) |
Across all 22 studies, recruiting or not: 0% stop at 75 or younger and 0% at 65; 36% take children; 0% are for women only and 0% for men only; 9% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 13, 2026.
Studies
Recruiting first, then most recently updated. Showing 22 of 22. search them.
- Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman DiseaseRecruitingNCT033008301 country
- A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFHRecruitingNCT052839931 country
- Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman DiseaseRecruitingNCT07085039Phase 21 country
- International Registry for Patients With Castleman DiseaseRecruitingNCT028179971 country
- Registry for Adults With Plasma Cell Disorders (PCD's)RecruitingNCT037178441 country
- AutoInflammatory Disease Alliance Registry (AIDA)RecruitingNCT0520071522 countries
- An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life ContextRecruitingNCT067208701 country
- Nintedanib Treatment in Unicentric Castleman DiseaseNot yet recruitingNCT06643091Phase 2
- HHV8 and Solid Organ TransplantationRecruitingNCT050811411 country
- Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign DiseaseTerminatedNCT01552434Phase 11 country
- Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms and Castleman DiseaseSuspendedNCT05028621Not applicable1 country
- Sirolimus in Previously Treated Idiopathic Multicentric Castleman DiseaseActive, not recruitingNCT03933904Phase 21 country
- Unicentric Form of Castleman Disease - Surgery Therapy BenefitCompletedNCT05440305
- Tocilizumab for KSHV-Associated Multicentric Castleman DiseaseCompletedNCT01441063Phase 21 country
- Unlock the Cell: Castleman's Disease Flow Cytometry StudyCompletedNCT028539681 country
- Castleman Disease Collaborative Network BiobankWithdrawnNCT028710501 country
- Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's DiseaseWithdrawnNCT00361933Phase 4
- A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra TreatmentCompletedNCT01183598Phase 11 country
- Nelfinavir for the Treatment of Gammaherpesvirus-Related TumorsTerminatedNCT02080416Early Phase 11 country
- A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's DiseaseCompletedNCT00412321Phase 11 country
- Dose-escalation Study of Oral CX-4945Status unknownNCT00891280Phase 11 country
- Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on ChemotherapyTerminatedNCT00127569Phase 2